Is the Pannexin-1 channel a mechanism underlying hypertension in humans? A translational study of human hypertension
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Is the Pannexin-1 channel a mechanism underlying hypertension in humans? A translational study of human hypertension. / Gliemann, Lasse; Tamariz-Ellemann, Andrea; Hansen, Camilla Collin; Ehlers, Thomas Svare; Møller, Sophie; Hellsten, Ylva.
In: Hypertension, Vol. 79, No. 5, 2022, p. 1132-1143.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Is the Pannexin-1 channel a mechanism underlying hypertension in humans? A translational study of human hypertension
AU - Gliemann, Lasse
AU - Tamariz-Ellemann, Andrea
AU - Hansen, Camilla Collin
AU - Ehlers, Thomas Svare
AU - Møller, Sophie
AU - Hellsten, Ylva
N1 - CURIS 2022 NEXS 080
PY - 2022
Y1 - 2022
N2 - Background: In preclinical models, the pannexin-1 channel has been shown to be involved in blood pressure regulation through an effect on peripheral vascular resistance. Pannexin-1 releases ATP, which can activate constrictive purinergic receptors on the smooth muscle cells. Pannexin-1 opening is proposed to be mediated by α-adrenergic receptors to potentiate sympathetic constriction. This positions pannexin-1 as a putative pharmacological target in blood pressure regulation in humans. The aim was to provide the first translational evidence for a role of pannexin-1 in essential hypertension in humans by use of an advanced invasive mechanistic approach.Methods: Middle-aged stage-1 hypertensive (n=13; 135.7±6.4 over 83.7±3.7 mm Hg) and normotensive men (n=12; 117.3±5.7 over 72.2±3.5 mm Hg) were included. Blood pressure and leg vascular resistance were determined during femoral arterial infusion of tyramine (α-adrenergic receptor stimulation), sodium nitroprusside, and acetylcholine. Measurements were made during control conditions and with Pannexin-1 blockade (3000 mg probenecid). Expression of Pannexin-1, purinergic- and α-adrenergic receptors in skeletal muscle biopsies was determined by Western blot.Results: The changes in leg vascular resistance in response to tyramine (+289% versus +222%), sodium nitroprusside (-82% versus -78%) and acetylcholine (-40% versus -44%) infusion were not different between the 2 groups (P>0.05) and Pannexin-1 blockade did not alter these variables (P>0.05). Expression of Pannexin-1 and of purinergic- and α-adrenergic receptors was not different between the 2 groups (P>0.05).Conclusions: Contrary to our hypothesis, the data demonstrate that pannexin-1 does not contribute to the elevated blood pressure in essential hypertension, a finding, which also opposes that reported in preclinical models.
AB - Background: In preclinical models, the pannexin-1 channel has been shown to be involved in blood pressure regulation through an effect on peripheral vascular resistance. Pannexin-1 releases ATP, which can activate constrictive purinergic receptors on the smooth muscle cells. Pannexin-1 opening is proposed to be mediated by α-adrenergic receptors to potentiate sympathetic constriction. This positions pannexin-1 as a putative pharmacological target in blood pressure regulation in humans. The aim was to provide the first translational evidence for a role of pannexin-1 in essential hypertension in humans by use of an advanced invasive mechanistic approach.Methods: Middle-aged stage-1 hypertensive (n=13; 135.7±6.4 over 83.7±3.7 mm Hg) and normotensive men (n=12; 117.3±5.7 over 72.2±3.5 mm Hg) were included. Blood pressure and leg vascular resistance were determined during femoral arterial infusion of tyramine (α-adrenergic receptor stimulation), sodium nitroprusside, and acetylcholine. Measurements were made during control conditions and with Pannexin-1 blockade (3000 mg probenecid). Expression of Pannexin-1, purinergic- and α-adrenergic receptors in skeletal muscle biopsies was determined by Western blot.Results: The changes in leg vascular resistance in response to tyramine (+289% versus +222%), sodium nitroprusside (-82% versus -78%) and acetylcholine (-40% versus -44%) infusion were not different between the 2 groups (P>0.05) and Pannexin-1 blockade did not alter these variables (P>0.05). Expression of Pannexin-1 and of purinergic- and α-adrenergic receptors was not different between the 2 groups (P>0.05).Conclusions: Contrary to our hypothesis, the data demonstrate that pannexin-1 does not contribute to the elevated blood pressure in essential hypertension, a finding, which also opposes that reported in preclinical models.
KW - Faculty of Science
KW - Acetylcholine
KW - Blood pressure
KW - Cardiac output
KW - Probenecid
KW - Tyramine
U2 - 10.1161/HYPERTENSIONAHA.121.18549
DO - 10.1161/HYPERTENSIONAHA.121.18549
M3 - Journal article
C2 - 35291811
VL - 79
SP - 1132
EP - 1143
JO - Hypertension
JF - Hypertension
SN - 0194-911X
IS - 5
ER -
ID: 300453428